Canigen Parvo-C Lyophilisate for Suspension for Injection

Kraj: Wielka Brytania

Język: angielski

Źródło: VMD (Veterinary Medicines Directorate)

Składnik aktywny:

Canine parvovirus

Dostępny od:

MSD Animal Health UK Limited

Kod ATC:

QI07AD01

INN (International Nazwa):

Canine parvovirus

Forma farmaceutyczna:

Suspension for injection

Typ recepty:

POM-V - Prescription Only Medicine – Veterinarian

Grupa terapeutyczna:

Dogs

Dziedzina terapeutyczna:

Live Viral Vaccine

Status autoryzacji:

Authorized

Data autoryzacji:

2007-08-01

Charakterystyka produktu

Revised: May 2023
AN: 02112/2022
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Canigen Parvo-C lyophilisate for suspension for injection for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 ml dose contains:
ACTIVE SUBSTANCE:
Live canine parvovirus (CPV), strain 154

10
7.0
TCID
50
*
*Tissue culture infective dose 50%
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lyophilisate for suspension for injection.
Lyophilisate: off-white or cream-coloured pellet.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, INCLUDING TARGET SPECIES
For active immunisation of dogs to prevent mortality, clinical signs
and viral excretion
following canine parvovirus infection.
Onset of immunity: 1 week.
Duration of immunity: 3 years.
4.3
CONTRAINDICATIONS
None.
4.4
SPECIFIC WARNINGS FOR EACH TARGET SPECIES
Vaccinate healthy animals only.
The vaccine may not be effective in dogs incubating the disease at the
time of
vaccination.
A good immune response is reliant on the reaction of an immunogenic
agent and a fully
Revised: May 2023
AN: 02112/2022
Page 2 of 6
competent immune system. Immunocompetence of the animal may be
compromised by
a variety of factors including poor health, nutritional status,
genetic factors, concurrent
drug therapy and stress.
The immunogenicity of the vaccine antigen will be reduced by poor
storage or
inappropriate administration.
The vaccine has been proved to be of benefit against virulent
challenge in the presence
of maternal antibody levels to CPV that are likely to be encountered
under field
conditions.
Experience has shown that the maternal antibody status of pups within
a litter varies
greatly, and reliance should not be placed on serological examination
of the bitch alone.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals:
Animals that have received a corresponding anti-serum or
immunosuppressive drugs
should not be vaccinated until an interval of at least 4 weeks has
elapsed.
Vacci